|Title:||Itraconazole prophylaxis for invasive Aspergillus infection in lung transplantation.|
|Authors:||Kato, K |
Nagao, M https://orcid.org/0000-0002-8886-6145 (unconfirmed)
Matsumura, Y https://orcid.org/0000-0001-8595-8944 (unconfirmed)
|Author's alias:||長尾, 美紀|
invasive Aspergillus infection
therapeutic drug monitoring
|Journal title:||Transplant infectious disease|
|Abstract:||Invasive Aspergillus infection (IA) is a significant cause of morbidity in lung transplantation (LT). However, its optimal prophylaxis is unclear. We routinely administer itraconazole (ITCZ) prophylaxis to all patients undergoing LT. In this study, we retrospectively evaluated the duration of prophylaxis and risk factors of IA. Among 30 adult patients who underwent LT, 5 patients developed IA. All patients with IA stopped ITCZ treatment within 1 year. At least 1 year of ITCZ prophylaxis is essential for the prevention of IA. Cytomegalovirus infection, renal replacement therapy, and tracheotomy were risk factors for IA.|
|Rights:||This is the peer reviewed version of the following article: K. Kato, M. Nagao, S. Nakano, T. Yunoki, G. Hotta, M. Yamamoto, Y. Matsumura, Y. Ito, S. Takakura, F. Chen, T. Bando, Y. Matsuda, K. Matsubara, H. Date, S. Ichiyama. Itraconazole prophylaxis for invasive Aspergillus infection in lung transplantation. Transpl Infect Dis 2014: 16: 340–343, which has been published in final form at http://dx.doi.org/10.1111/tid.12187. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.|
この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。This is not the published version. Please cite only the published version.
|Appears in Collections:||Journal Articles |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.